OMass Therapeutics’ Founder & Scientific Advisor, Professor Carol Robinson, receives a Royal Society Medal

Published

July 23, 2019

OMass Therapeutics’ Founder & Scientific Advisor, Professor Carol Robinson, receives a Royal Society Medal

Oxford, 23 July 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today announced that the Company’s Founder, Professor Carol Robinson, has been awarded a Royal Society Medal.

The Royal Medal was awarded to Carol for her pioneering work on structural biology improving the understanding of proteins, their interactions and functional regulation. The Royal Medals are one of the Royal Society’s most prestigious awards that recognise exceptional researchers who make outstanding contributions to science and are made annually on behalf of the Queen.

Professor Dame Carol Robinson, Founder & Scientific Advisor, OMass Therapeutics commented:
“I am truly honoured to be acknowledged with this award. Over the years, I have been present at several Royal Society Medal Award ceremonies and have always been very impressed by the recipients. I am delighted to be joining this distinguished group of scientists.”

– Ends –

Further information:

J
W Communications
Julia Wilson
+44(0)7818 430877
juliawilsonuk@gmail.com

Notes for Editors:

About OMass Therapeutics
OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane proteins, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Sciences Innovation. For further information please visit the Company’s website at: www.omass.com

MORERelated News
OMass Therapeutics appoints Dr Nathalie Franchimont as Non-Executive Director
Oxford, 28 July 2020 – OMass Therapeutics (“OMass”), a biopharmaceutical company harnessing native mass spectrometry and other high definition biophysical...
OMass Announces Publication in Nature Methods
Oxford, 15 May 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in...
OMass Announces Acquisition of Pharmacology Capabilities from Excellerate Biosciences
Oxford, 25 February 2020 - OMass acquires a pharmacology team led by industry expert, Professor Steven Charlton - OMass Therapeutics...